Crescent Biopharma CBIO Stock
Crescent Biopharma Price Chart
Crescent Biopharma CBIO Financial and Trading Overview
| Crescent Biopharma stock price | 13.98 USD |
| Previous Close | 16.44 USD |
| Open | 16.37 USD |
| Bid | 11.77 USD x 200 |
| Ask | 21.15 USD x 200 |
| Day's Range | 14.71 - 16.47 USD |
| 52 Week Range | 8.72 - 27.41 USD |
| Volume | 134.87K USD |
| Avg. Volume | 404.8K USD |
| Market Cap | 549.4M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.14 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.6 USD |
CBIO Valuation Measures
| Enterprise Value | 537.49M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.623574 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 46.234257 |
| Price/Book (mrq) | 3.1032314 |
| Enterprise Value/Revenue | 45.232 |
| Enterprise Value/EBITDA | -3.161 |
Trading Information
Crescent Biopharma Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 26.65% |
| S&P500 52-Week Change | 16.97% |
| 52 Week High | 27.41 USD |
| 52 Week Low | 8.72 USD |
| 50-Day Moving Average | 17.04 USD |
| 200-Day Moving Average | 15.71 USD |
CBIO Share Statistics
| Avg. Volume (3 month) | 404.8K USD |
| Avg. Daily Volume (10-Days) | 635.44K USD |
| Shares Outstanding | 37.14M |
| Float | 26.65M |
| Short Ratio | 17.58 |
| % Held by Insiders | 0.27% |
| % Held by Institutions | 82.87% |
| Shares Short | 3.17M |
| Short % of Float | 14.66% |
| Short % of Shares Outstanding | 8.54% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1432.63% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | N/A |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 11.88M USD |
| Revenue Per Share (ttm) | 0.43 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 11.88M USD |
| EBITDA | -170028000 USD |
| Net Income Avi to Common (ttm) | -165124000 USD |
| Diluted EPS (ttm) | -0.14 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 171.59M USD |
| Total Cash Per Share (mrq) | 4.01 USD |
| Total Debt (mrq) | 1.44M USD |
| Total Debt/Equity (mrq) | 0.88 USD |
| Current Ratio (mrq) | 9.657 |
| Book Value Per Share (mrq) | 4.766 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -72679000 USD |
| Levered Free Cash Flow (ttm) | N/A |
Profile of Crescent Biopharma
| Country | United States |
| State | MA |
| City | Waltham |
| Address | 300 Fifth Avenue |
| ZIP | 02451 |
| Phone | 617 460 5595 |
| Website | https://crescentbiopharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 69 |
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Q&A For Crescent Biopharma Stock
What is a current CBIO stock price?
Crescent Biopharma CBIO stock price today per share is 13.98 USD.
How to purchase Crescent Biopharma stock?
You can buy CBIO shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Crescent Biopharma?
The stock symbol or ticker of Crescent Biopharma is CBIO.
Which industry does the Crescent Biopharma company belong to?
The Crescent Biopharma industry is Biotechnology.
How many shares does Crescent Biopharma have in circulation?
The max supply of Crescent Biopharma shares is 37.15M.
What is Crescent Biopharma Price to Earnings Ratio (PE Ratio)?
Crescent Biopharma PE Ratio is now.
What was Crescent Biopharma earnings per share over the trailing 12 months (TTM)?
Crescent Biopharma EPS is -0.14 USD over the trailing 12 months.
Which sector does the Crescent Biopharma company belong to?
The Crescent Biopharma sector is Healthcare.
Crescent Biopharma CBIO included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26924.39 USD — |
-0.06
|
1.9B USD — | 26876.27 USD — | 27077.95 USD — | — - | 1.9B USD — |
|
US Tech Composite Total Return
XCMP
US
|
33220.93 USD — |
-0.16
|
— — | 33196.83 USD — | 33445.94 USD — | — - | — — |
|
US Tech Capital Market Composite
RCMP
US
|
135.14 USD — |
-0.87
|
— — | 135.08 USD — | 136.92 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1321.39 USD — |
-0.63
|
— — | 1321.32 USD — | 1333.04 USD — | — - | — — |
- {{ link.label }} {{link}}
